Sanofi-Aventis Q3 Results - Q3 Top Pharma Company Earnings Reports

View Sanofi-Aventis' Q3 Earnings Report


  • Good performances from Lovenox(R) (+13.7%) and Lantus(R) (+21.7%) across all three geographic regions, continuation of strong uptrend in the presence of Plavix(R) in the United States (+11.3%) and Japan (+50.3%)
  • Sales growth of 20.9% in emerging markets
  • Strong growth for the Pentacel(R) and Menactra(R) vaccines; substantial proportion of seasonal and A/H1N1 vaccines sales anticipated in the fourth quarter
  • OTC sales up 26.3%
  • Launch of Multaq(R) in the United States on target; positive opinion from the CHMP in Europe, and approval in Canada and Switzerland
  • Impact of competition from generics of Eloxatin(R) in the United States and Plavix(R) in some European countries more than offset by growth drivers

Check out Sanofi-Aventis' current earnings estimates from CNN Money

Sanofi-Aventis' Website:

Sanofi-Aventis Q3 Results - Q3 Top Pharma Company Earnings Reports

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.